Advertisement
Advertisement

AKRO

AKRO logo

Akero Therapeutics, Inc. Common Stock

36.00
USD
-0.73
-1.98%
Apr 07, 16:00 UTC -4
Closed
exchange

Pre-Market

35.90

-0.07
-0.21%

Akero Therapeutics, Inc. Common Stock Profile

About

Akero Therapeutics Inc. is a clinical-stage biotechnology company. It is focused on developing transformational treatments for non-alcoholic steatohepatitis and other serious metabolic disorders. The company's product pipeline consists of AKR-001, for the treatment of non-alcoholic steatohepatitis, which are in clinical stage. Akero Therapeutics Inc. is based in San Francisco, United States.

Info & Links

CEO

Andrew Cheng

Headquarters

601 GATEWAY BOULEVARD, SUITE 350
SOUTH SAN FRANCISCO, CA 94080, UNITED STATES

Industry

Medical Biomedical And Genetics

Sector

Medical

Website

www.akerotx.com

Auditor

Deloitte & Touche LLP

Share holders

4

Employees

63

Akero Therapeutics, Inc. Common Stock Statistics

Valuation Measures

Market Capitalization2

2.86B

Enterprise Value

2.55B

Enterprise Value/EBITDA(ttm)

-8.57

Price to Earnings Ratio(ttm)

--

Price to Sales(ttm)

--

Price to Book(mrq)

4.76

Price to Cash(ytd)

--

Profitability

Gross Margin(ttm)

0.00%

Operating Margin(ttm)

--

Profit Margin(ttm)

0.00%

Return on Equity(ttm)

-32.46%

Return on Invested Capital(ttm)

-31.08%

Return on Assets(ttm)

-29.83%

Income Statement

Revenue(ttm)

0.00

Revenue Per Share(ttm)

0.00

Gross Profit(ttm)

0.00

EBITDA(ttm)3

-297.92M

Net Income Available to Common(ttm)

-252.06M

Diluted EPS(ttm)

-3.75

Share Statistics

Beta (5Y Monthly)

-0.11

52-Week Change

55.05%

S&P 500 52-Week Change

-2.69%

S&P 500 Member

Yes

Stock Optionable

Yes

Total Shares Outstanding1

79.62M

Dividend Yield

0.00%

Float4

64.26M

% Held by Insiders

7.94%

% Held by Institutions

--

Balance Sheet

Total Cash(mrq)

743.08M

Total Cash Per Share(mrq)

9.33

Total Debt(mrq)

35.49M

Total Debt/Equity(mrq)

4.73%

Current Ratio(mrq)

19.38%

Quick Ratio(mrq)

17.25%

Book Value Per Share(mrq)

10.36

Cash Flow

Operating Cash Flow Per Share(ytd)

-3.43

Free Cash Flow(ytd)

-230.11M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.

  • 1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
  • 2 Market Cap is calculated using total shares outstanding and the most recent share price.
  • 3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
  • 4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.
Advertisement